The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Open accessAbstract
BACKGROUND: CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of patients. METHODS: We conducted a phase 1 trial involving adults with relapsed B-cell ALL who received an infusion of autologous T cells expressing the 19-28z CAR at the Memorial Sloan Kettering Cancer Center (MSKCC). Safety and long-term outcomes were assessed, as were their associations with demographic, clinical, and disease characteristics. RESULTS: A total of 53 adults received 19-28z CAR T cells that were manufactured at MSKCC. After infusion, severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15 to 40); 1 patient died. Complete remission was observed in 83% of the patients. At a median follow-up of 29 months (range, 1 to 65), the median event-free survival was 6.1 months (95% CI, 5.0 to 11.5), and the median overall survival was 12.9 months (95% CI, 8.7 to 23.4). Patients with a low disease burden (<5% bone marrow blasts) before treatment had markedly enhanced remission duration and survival, with a median event-free survival of 10.6 months (95% CI, 5.9 to not reached) and a median overall survival of 20.1 months (95% CI, 8.7 to not reached). Patients with a higher burden of disease (≥5% bone marrow blasts or extramedullary disease) had a greater incidence of the cytokine release syndrome and neurotoxic events and shorter long-term survival than did patients with a low disease burden. CONCLUSIONS: In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Self-citationBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citationT-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S. M., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,444
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,293
Self-citationTopp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 914
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,004
Cytokines in CAR T Cell–Associated Neurotoxicity
Gust, J., Ponce, R. A., Liles, W. C., Garden, G. A., & Turtle, C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577027 · Cited by 279
Sheih, A., Voillet, V., Hanafi, L., DeBerg, H. A., Yajima, M., Hawkins, R. M., Gersuk, V. H., Riddell, S. R., Maloney, D. G., Wohlfahrt, M. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13880-1 · Cited by 268
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Gust, J., Taraseviciute, A., & Turtle, C. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0582-9 · Cited by 267
Wang, N., Hu, X., Cao, W., Li, C., Xiao, Y., Cao, Y., Gu, C., Zhang, S., Chen, L., Cheng, J., et al. (2019) · Blood · doi:10.1182/blood.2019000017 · Cited by 263
Stein-Thoeringer, C. K., Saini, N. Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U., Fante, M. A., Schmidt, S., Hayase, E., Hayase, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02234-6 · Cited by 255
Self-citationAcute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Brown, P. A., Shah, B. D., Advani, A. S., Aoun, P. A., Boyer, M. W., Burke, P. W., DeAngelo, D. J., Dinner, S. N., Fathi, A. T., Gauthier, J., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0042 · Cited by 260
Self-citationHypoxia as a driver of resistance to immunotherapy
Kopecka, J., Salaroglio, I. C., Pérez-Ruiz, E., Sarmento‐Ribeiro, A. B., Saponara, S., Rivas, J. D. L., & Riganti, C. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100787 · Cited by 264
Arcangeli, S., Bove, C., Mezzanotte, C., Camisa, B., Falcone, L., Manfredi, F., Bezzecchi, E., Khoury, R. E., Norata, R., Sanvito, F., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150807 · Cited by 259
Kuhn, N. F., Purdon, T. J., van Leeuwen, D. G., Lopez, A. V., Curran, K. J., Daniyan, A. F., & Brentjens, R. J. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.006 · Cited by 255
Self-citationGenetically engineered T cells for cancer immunotherapy
Li, D., Li, X., Zhou, W.-L., Huang, Y., Liang, X., Jiang, L., Yang, X., Sun, J., Li, Z., Han, W., et al. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0070-9 · Cited by 255
Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies
Li, H., Peng, K., Yang, K., Ma, W., Qi, S., Yu, X., He, J., Lin, X., & Yu, G. (2022) · Theranostics · doi:10.7150/thno.77350 · Cited by 256
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 244
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Pinnix, C. C., Gunther, J. R., Dabaja, B. S., Strati, P., Fang, P., Hawkins, M., Adkins, S., Westin, J. R., Ahmed, S., Fayad, L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001837 · Cited by 239
Cancer immunotherapy: broadening the scope of targetable tumours
van den Bulk, J., Verdegaal, E. M. E., & de Miranda, N. F. C. C. (2018) · Open Biology · doi:10.1098/rsob.180037 · Cited by 244
Wang, Y., Tong, C., Dai, H., Wu, Z., Han, X., Guo, Y., Chen, D., Wei, J., Ti, D., Liu, Z. Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20696-x · Cited by 241
Self-citationChen, Y., Abila, B., & Kamel, Y. M. (2023) · Cancers · doi:10.3390/cancers15030663 · Cited by 251
Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL
Sheth, V., & Gauthier, J. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01134-4 · Cited by 244
Schultz, L. M., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J. E., Stefanski, H. E., Talano, J.-A., Moskop, A. M., Margossian, S. P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03585 · Cited by 236
Self-citationThe landscape of bispecific T cell engager in cancer treatment
Zhou, S., Liu, M., Ren, F., Meng, X., & Yu, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00294-9 · Cited by 240
Pennisi, M., Sánchez‐Escamilla, M., Flynn, J. R., Shouval, R., Tomás, A. A., Silverberg, M. L., Batlevi, C. L., Brentjens, R. J., Dahi, P. B., Devlin, S. M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003885 · Cited by 233
Self-citationMemory T cell, exhaustion, and tumor immunity
Ando, M., Ito, M., Srirat, T., Kondo, T., & Yoshimura, A. (2019) · Immunological Medicine · doi:10.1080/25785826.2019.1698261 · Cited by 233
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
Gang, M., Marín, N. D., Wong, P., Neal, C. C., Marsala, L. I., Foster, M., Schappe, T., Meng, W., Tran, J., Schaettler, M. O., et al. (2020) · Blood · doi:10.1182/blood.2020006619 · Cited by 236
Self-citationBrown, P. A., Inaba, H., Annesley, C., Beck, J. C., Colace, S. I., Dallas, M. H., DeSantes, K. B., Kelly, K. M., Kitko, C. L., Lacayo, N. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0001 · Cited by 229
Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 229
Freyer, C. W., & Porter, D. L. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.025 · Cited by 216
Zhang, X., Lu, X., Yang, J., Zhang, G., Li, J., Song, L., Su, Y., Shi, Y., Zhang, M., He, J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001466 · Cited by 220
NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates
Yang, D., Sun, B., Li, S., Wei, W., Liu, X., Cui, X., Zhang, X., Liu, N., Yan, L., Deng, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add1951 · Cited by 217
Principles of adoptive T cell therapy in cancer
Met, Ö., Mølgaard, K., Chamberlain, C. A., Donia, M., & Svane, I. M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0703-z · Cited by 219
Whilding, L. M., Halim, L., Draper, B., Parente‐Pereira, A. C., Zabinski, T., Davies, D. M., & Maher, J. F. (2019) · Cancers · doi:10.3390/cancers11050674 · Cited by 217
CAR-T Cell Therapy: the Efficacy and Toxicity Balance
Chohan, K. L., Siegler, E. L., & Kenderian, S. S. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00687-7 · Cited by 227
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
Upadhyay, R., Boiarsky, J., Pantsulaia, G., Svensson‐Arvelund, J., Lin, M. J., Wroblewska, A., Bhalla, S., Scholler, N., Bot, A. I., Rossi, J. M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0756 · Cited by 216
Rejeski, K., Perez, A. P., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C. D. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004475 · Cited by 210
Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
Agarwalla, P., Ogunnaike, E. A., Ahn, S., Froehlich, K. A., Jansson, A., Ligler, F. S., Dotti, G., & Brudno, Y. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01245-x · Cited by 216
Kadauke, S., Myers, R. M., Li, Y., Aplenc, R., Baniewicz, D., Barrett, D. M., Leahy, A. B., Callahan, C. A., Dolan, J. G., Fitzgerald, J. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02477 · Cited by 208
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy
Chong, E. A., Alanio, C., Svoboda, J., Nasta, S. D., Landsburg, D. J., Lacey, S. F., Ruella, M., Bhattacharyya, S., Wherry, E. J., & Schuster, S. J. (2021) · Blood · doi:10.1182/blood.2021012634 · Cited by 209
Gauthier, J., Bezerra, E. D., Hirayama, A. V., Fiorenza, S., Sheih, A., Chou, C. K., Kimble, E. L., Pender, B. S., Hawkins, R. M., Vakil, A., et al. (2021) · Blood · doi:10.1182/blood.2020006770 · Cited by 205
Shah, B. D., Bishop, M. R., Oluwole, O. O., Logan, A. C., Baer, M. R., Donnellan, W. B., O’Dwyer, K. M., Holmes, H. E., Arellano, M. L., Ghobadi, A., et al. (2021) · Blood · doi:10.1182/blood.2020009098 · Cited by 209
Self-citationSynthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response
Baeuerle, P. A., Ding, J. P., Patel, E. S., Thorausch, N., Horton, H. M., Gierut, J. J., Scarfò, I., Choudhary, R., Kiner, O., Krishnamurthy, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10097-0 · Cited by 212
Impact of Manufacturing Procedures on CAR T Cell Functionality
Watanabe, N., Mo, F., & McKenna, M. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876339 · Cited by 206
CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions
Hunter, B. D., & Jacobson, C. A. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz017 · Cited by 200
Cancer immunotherapy: Challenges and limitations
Taefehshokr, S., Parhizkar, A., Hayati, S., Mousapour, M., Mahmoudpour, A., Eid, L. E., Rahmanpour, D., Fattahi, S., Shabani, H., & Taefehshokr, N. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153723 · Cited by 204
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
Saura‐Esteller, J., de Jong, M., King, L. A., Ensing, E., Winograd, B., de Gruijl, T. D., Parren, P. W. H. I., & van der Vliet, H. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915837 · Cited by 210
Pagliaro, L., Chen, S., Herranz, D., Mecucci, C., Harrison, C. J., Mullighan, C. G., Zhang, M., Zhu, C. H., Boissel, N., Winter, S. S., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00525-x · Cited by 202
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Sweeney, M., Corden, B., & Cook, S. A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910865 · Cited by 202
Jain, T., Bar, M., Kansagra, A. J., Chong, E. A., Hashmi, S. K., Neelapu, S. S., Byrne, M. T., Jacoby, E., Lazaryan, A., Jacobson, C. A., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.08.015 · Cited by 196
Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapy
Gust, J., Finney, O. C., Li, D., Brakke, H., Hicks, R. M., Futrell, R. B., Gamble, D. N., Rawlings-Rhea, S. D., Khalatbari, H. K., Ishak, G. E., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25502 · Cited by 199
Self-citationSleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities
Magnani, C. F., Gaipa, G., Lussana, F., Belotti, D., Gritti, G., Napolitano, S., Matera, G., Cabiati, B., Buracchi, C., Borleri, G., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138473 · Cited by 201
Genetics and prognosis of ALL in children vs adults
Roberts, K. G. (2018) · Hematology · doi:10.1182/asheducation-2018.1.137 · Cited by 204
Xu, Y., Liu, Q., Zhong, M., Wang, Z., Chen, Z., Zhang, Y., Xing, H., Tian, Z., Tang, K., Liao, X., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0732-7 · Cited by 196
Myers, R. M., Li, Y., Leahy, A. B., Barrett, D. M., Teachey, D. T., Callahan, C. A., Fasano, C., Rheingold, S. R., DiNofia, A. M., Wray, L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03458 · Cited by 194
Fultang, L., Booth, S., Yogev, O., Costa, B. M. D., Tubb, V., Panetti, S., Stavrou, V., Scarpa, U., Jankevics, A., Lloyd, G. R., et al. (2020) · Blood · doi:10.1182/blood.2019004500 · Cited by 190
HLA-independent T cell receptors for targeting tumors with low antigen density
Mansilla-Soto, J., Eyquem, J., Haubner, S., Hamieh, M., Feucht, J., Paillon, N., Zucchetti, A. E., Li, Z., Sjöstrand, M., Lindenbergh, P. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01621-1 · Cited by 190
Self-citationPark, J. H., Nath, K., Devlin, S. M., Sauter, C. S., Palomba, M. L., Shah, G. L., Dahi, P. B., Lin, R. J., Scordo, M., Perales, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02404-6 · Cited by 196
Self-citationEnhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting
Rotolo, A., Caputo, V. S., Holubová, M., Baxan, N., Dubois, O., Chaudhry, M. S., Xiao, X., Goudevenou, K., Pitcher, D. S., Petevi, K., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.017 · Cited by 194
Making CAR T Cells a Solid Option for Solid Tumors
Schmidts, A., & Maus, M. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02593 · Cited by 193
Guedan, S., Madar, A., Casado‐Medrano, V., Shaw, C. E., Wing, A., Liu, F., Young, R. M., June, C. H., & Posey, A. D. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133215 · Cited by 190
Introduction to the Immune System
McComb, S., Thiriot, A., Akache, B., Krishnan, L., & Stark, F. C. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9597-4_1 · Cited by 186
CAR T‐cell therapy: Full speed ahead
Sermer, D. J., & Brentjens, R. J. (2019) · Hematological Oncology · doi:10.1002/hon.2591 · Cited by 189
Self-citationLickefett, B., Chu, L., Ortiz‐Maldonado, V., Warmuth, L., Barba, P., Doglio, M., Henderson, D. A., Hudecek, M., Kremer, A., Markman, J. L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303935 · Cited by 200
Cytokine Release Syndrome: Current Perspectives
Murthy, H. S., Iqbal, M., Chávez, J. C., & Kharfan‐Dabaja, M. A. (2019) · ImmunoTargets and Therapy · doi:10.2147/itt.s202015 · Cited by 188
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 197
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
Stoiber, S., Cadilha, B. L., Benmebarek, M.-R., Lesch, S., Endres, S., & Kobold, S. (2019) · Cells · doi:10.3390/cells8050472 · Cited by 182
Hay, K. A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15644 · Cited by 177
CAR T Cell Toxicity: Current Management and Future Directions
Yáñez, L., Sánchez‐Escamilla, M., & Perales, M. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000186 · Cited by 180
PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
McGowan, E. M., Lin, Q., Ma, G., Yin, H., Chen, S., & Lin, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109625 · Cited by 182
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Shah, N. N., Maatman, T. C., Hari, P., & Johnson, B. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00146 · Cited by 181
Allogeneic CAR-T Cells: More than Ease of Access?
Graham, C., Jóźwik, A., Pepper, A. G. S., & Benjamin, R. (2018) · Cells · doi:10.3390/cells7100155 · Cited by 178
Pennisi, M., Jain, T., Santomasso, B., Mead, E., Wudhikarn, K., Silverberg, M. L., Batlevi, Y., Shouval, R., Devlin, S. M., Batlevi, C. L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000952 · Cited by 175
Self-citationSamra, B., Jabbour, E. J., Ravandi, F., Kantarjian, H. M., & Short, N. J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00905-2 · Cited by 176
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
Fultang, L., Panetti, S., Ng, M. H. L., Collins, P. J., Graef, S., Rizkalla, N., Booth, S., Lenton, R., Noyvert, B., Shannon-Lowe, C. D., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.025 · Cited by 170
Sato, Y., Bando, H., Piazza, M., Gowing, G., Herberts, C. A., Jackman, S. M., Leoni, G., Libertini, S., MacLachlan, T. K., McBlane, J. W., et al. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.10.001 · Cited by 172
Counteracting CAR T cell dysfunction
Poorebrahim, M., Melief, J., de Coaña, Y. P., Wickström, S. L., Arregui, A. C., & Kiessling, R. W. (2020) · Oncogene · doi:10.1038/s41388-020-01501-x · Cited by 172
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 178
Ortiz‐Maldonado, V., Rives, S., Castellà, M., Alonso‐Saladrigues, A., Benítez‐Ribas, D., Caballero‐Baños, M., Baumann, T., Cid, J., García‐Rey, E., Llanos, C., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.027 · Cited by 176
Bai, Z., Woodhouse, S., Zhao, Z., Arya, R., Govek, K., Kim, D., Lundh, S., Baysoy, A., Sun, H., Deng, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj2820 · Cited by 166
Genetic engineering of T cells for immunotherapy
Ellis, G. I., Sheppard, N. C., & Riley, J. L. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00329-9 · Cited by 170
Wermke, M., Kraus, S., Ehninger, A., Bargou, R. C., Goebeler, M.-E., Middeke, J. M., Kreissig, C., Bonin, M. V., Koedam, J., Pehl, M., et al. (2021) · Blood · doi:10.1182/blood.2020009759 · Cited by 166
How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy
Jain, M. D., Smith, M. M., & Shah, N. N. (2023) · Blood · doi:10.1182/blood.2022017414 · Cited by 177
Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163
Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL
Pan, J., Zuo, S., Deng, B., Xu, X., Li, C., Zheng, Q., Ling, Z., Song, W., Xu, J., Duan, J., et al. (2019) · Blood · doi:10.1182/blood.2019003293 · Cited by 164
Shi, T., Song, X., Wang, Y., Liu, F., & Wei, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00683 · Cited by 168
Self-citationInefficient CAR-proximal signaling blunts antigen sensitivity
Gudipati, V., Rydzek, J., Perez, I. D., Gonçalves, V. D. R., Scharf, L., Königsberger, S., Lobner, E., Kunert, R., Einsele, H., Stockinger, H. S. J., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0719-0 · Cited by 175
Shah, N. N., Qin, H., Yates, B., Su, L., Shalabi, H., Raffeld, M. A., Ahlman, M. A., Stetler‐Stevenson, M., Yuan, C. M., Guo, S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000219 · Cited by 162
Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines
Liu, J., Liew, S. S., Wang, J., & Pu, K. (2021) · Advanced Materials · doi:10.1002/adma.202103790 · Cited by 161
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing
Jo, S., Das, S., Williams, A., Chrétien, A.-S., Pagliardini, T., Roy, A. L., Postigo, J., Clerre, D. L., Jahangiri, B., Chion-Sotinel, I., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30896-2 · Cited by 167
Li, W., Qiu, S., Chen, J., Jiang, S., Chen, W., Jiang, J., Wang, F., Si, W., Shu, Y., Wei, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.011 · Cited by 167
Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
Lee, J. B., Khan, D. H., Hurren, R., Xu, M., Na, Y., Kang, H., Mirali, S., Wang, X., Gronda, M., Jitkova, Y., et al. (2021) · Blood · doi:10.1182/blood.2020009081 · Cited by 165
Self-citationUse of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Sheykhhasan, M., Manoochehri, H., & Dama, P. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00418-1 · Cited by 165
The Past, Present, and Future of Non-Viral CAR T Cells
Moretti, A., Ponzo, M., Nicolette, C. A., Tcherepanova, I. Y., Biondi, A., & Magnani, C. F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867013 · Cited by 167
Current challenges and emerging opportunities of CAR-T cell therapies
Abreu, T. R., Fonseca, N. A., Gonçalves, N., & Moreira, J. N. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.047 · Cited by 159
Ying, Z., He, T., Wang, X., Zheng, W., Lin, N., Tu, M., Xie, Y., Ping, L., Zhang, C., Liu, W., et al. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.08.002 · Cited by 157
Self-citationEmerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 160
Salter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., et al. (2021) · Science Signaling · doi:10.1126/scisignal.abe2606 · Cited by 165
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
Lamble, A. J., Myers, R. M., Taraseviciute, A., John, S., Yates, B., Steinberg, S. M., Sheppard, J., Kovach, A. E., Wood, B. L., Borowitz, M. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007423 · Cited by 161
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 170
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121491 · Cited by 156
4-1BB enhancement of CAR T function requires NF-κB and TRAFs
Li, G., Boucher, J. C., Kotani, H., Park, K., Zhang, Y., Shrestha, B., Wang, X., Guan, L., Beatty, N. J., Abate‐Daga, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121322 · Cited by 163
Self-citationBenjamin, R., Jain, N., Maus, M. V., Boissel, N., Graham, C., Jóźwik, A., Yallop, D., Konopleva, M. Y., Frigault, M. J., Teshima, T., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00245-9 · Cited by 158
Greco, B., Malacarne, V., Girardi, F. D., Scotti, G. M., Manfredi, F., Angelino, E., Sirini, C., Camisa, B., Falcone, L., Moresco, M. A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg3072 · Cited by 158
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
Metadata
- Authors
- Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., Roshal, M., Maslak, P., Davila, M., Brentjens, R. J., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From the Leukemia Service, Department of Medicine (J.H.P., C.S., P.M., R.J.B.), the Michael G. Harris Cell Therapy and Cell Engineering Facility (I.R., X.W., B. Sénéchal, Y.W.), the Center for Cell Engineering (J.H.P., I.R., X.W., R.J.B., M.S.), and the Departments of Epidemiology and Biostatistics (M.G.), Pediatrics (K.J.C.), Neurology (B. Santomasso), Anesthesiology and Critical Care Medicine (E.M.), and Pathology (M.R.), Memorial Sloan Kettering Cancer Center, and the Department of Medicine, Joan...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 449-459
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6637939
- OpenAlex
- W2787621143
- Cited by
- 2,688
- References
- 24
- Citations by year
- 2026: 164 · 2025: 235 · 2024: 306 · 2023: 351 · 2022: 365 · 2021: 403 · 2020: 412 · 2019: 290 · 2018: 156
- FWCI
- 118.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Comprehensive Cancer Network Foundation (Young Investigator Award)
- Emerald Foundation
- National Institute of Health (R01CA138738-05, P01CA059350, P01CA190174-01)
- Leukemia and Lymphoma Society (Career Development Award)
- American Society of Clinical Oncology (Career Development Award)
- Memorial Sloan Kettering Cancer Center Support Grant (P30CA008748)
- Juno Therapeutics
- Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center
- Stand Up To Cancer
- William Lawrence and Blanche Hughes Foundation
- Annual Terry Fox Run for Cancer Research
- Carson Family Charitable Trust
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD19 CAR T cells, B-cell acute lymphoblastic leukemia, relapsed leukemia, autologous T cell therapy, cytokine release syndrome, neurotoxicity, disease burden, bone marrow blasts, event-free survival, overall survival, long-term outcomes
- MeSH terms
- Adult, Aged, Follow-Up Studies, Humans, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Remission Induction, T-Lymphocytes, Survival Analysis, Cytokines, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
